glp 1 agonist drugs mechanism of action Frontiers GLP-1 Agonists For Obesity In

FDA Feds

Clinical trials are actively investigating GLP-1 Drugs for conditions like cardiovascular disease and liver disorders, with first approvals expected by 2025

Notably, up to 47% of T2D patients and 36% of non-T2D patients restarted their medication within the same timeframe

Then, in September, the Trump Administration launched a crackdown on deceptive direct-to-consumer drug advertising, resulting in the FDA publishing over 55 warning letters to online sellers of compounded versions of GLP-1 medications that called for the removal of false and misleading promotional statements, claims of clinically proven weight-loss treatments, and using the words FDA-approved in advertising copy

Step 8: Re-enrollment If you wish to continue receiving the medication through the Novo Nordisk Patient Assistance Program beyond your current approval period, you must re-enroll annually